Evidence map›Paper›PMID 22151236›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2012

Donor-specific indirect pathway analysis reveals a B-cell-independent signature which reflects outcomes in kidney transplant recipients.

L D Haynes, E Jankowska-Gan, A Sheka, M R Keller, M P Hernandez-Fuentes, R I Lechler, V Seyfert-Margolis, L A Turka, K A Newell, W J Burlingham

Registry-linked trialAbstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01338779 (Identification and Mechanistic Investigations of Tolerant Transplant Recipients), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01338779 completednot on this map

Identification and Mechanistic Investigations of Tolerant Transplant Recipients

TypeobservationalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2004 to 2015Enrolled197ConditionsTransplant Rejection, Kidney Transplantation, Renal Transplantation, Renal Transplant
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Activation and Regulation of Indirect Alloresponses in Transplanted Patients With Donor Specific Antibodies and Chronic Rejection.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Biomarkers in renal transplantation: An updated review.World journal of transplantation · 2017
    Review
  13. Observational
  14. Article
  15. Review
  16. Review
  17. Article
  18. Tolerant Kidney Transplant Patients Produce B Cells with Regulatory Properties.Journal of the American Society of Nephrology : JASN · 2015
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

L D HaynesDepartment of Surgery, Transplant Division, University of Wisconsin, Madison, WI, USA.
E Jankowska-Gan
A Sheka
M R Keller
M P Hernandez-Fuentes
R I Lechler
V Seyfert-Margolis
L A Turka
K A Newell
W J Burlingham

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Maternal Microchimerism and Neonatal ToleranceR01AI066219 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI BURLINGHAM, WILLIAM J · 2006 to 2016
$3.3M
Maternal Microchimerism and Neonatal ToleranceR56AI066219 · NIAID · UNIVERSITY OF WISCONSIN MADISON · PI BURLINGHAM, WILLIAM J · 2005 to 2005
$252k
Department of HealthMedical Research Council G0801537NCATS NIH HHS UL1 TR000454NCRR NIH HHS UL1 RR025008NIAID NIH HHS 1R01- AI066219NIAID NIH HHS R01 AI066219NIAID NIH HHS R56 AI066219
6 · The paper itself

Abstract

To investigate the role of donor-specific indirect pathway T cells in renal transplant tolerance, we analyzed responses in peripheral blood of 45 patients using the trans-vivo delayed-type hypersensitivity assay. Subjects were enrolled into five groups-identical twin, clinically tolerant (TOL), steroid monotherapy (MONO), standard immunosuppression (SI) and chronic rejection (CR)-based on transplant type, posttransplant immunosuppression and graft function. The indirect pathway was active in all groups except twins but distinct intergroup differences were evident, corresponding to clinical status. The antidonor indirect pathway T effector response increased across patient groups (TOL < MONO < SI < CR; p < 0.0001) whereas antidonor indirect pathway T regulatory response decreased (TOL > MONO = SI > CR; p < 0.005). This pattern differed from that seen in circulating naïve B-cell numbers and in a cross-platform biomarker analysis, where patients on monotherapy were not ranked closest to TOL patients, but rather were indistinguishable from chronically rejecting patients. Cross-sectional analysis of the indirect pathway revealed a spectrum in T-regulatory:T-effector balance, ranging from TOL patients having predominantly regulatory responses to CR patients having predominantly effector responses. Therefore, the indirect pathway measurements reflect a distinct aspect of tolerance from the recently reported elevation of circulating naïve B cells, which was apparent only in recipients off immunosuppression.

Indexed as

Tissue DonorsB-LymphocytesGraft RejectionHumansImmune ToleranceImmunosuppression TherapyKidney TransplantationPrognosisSignal TransductionT-Lymphocytes

Identifiers

PMID22151236
PMCPMC3374729

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.